Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMLA vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Topical anesthesia of intact skin for superficial procedures,Topical anesthesia of genital mucous membranes for minor superficial procedures,Local analgesia prior to lumbar puncture (off-label),Local analgesia prior to vaccination (off-label)
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
After topical application, the terminal elimination half-life of lidocaine is approximately 1.5-2 hours; prilocaine half-life is approximately 1.5 hours. In neonates, half-life may be prolonged due to immature hepatic function. Clinical context: Steady state is achieved within 12-24 hours with repeated application.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Lidocaine is primarily metabolized by CYP1A2 to monoethylglycinexylidide (MEGX) and further by CYP3A4; prilocaine is metabolized by amidases to o-toluidine metabolites that can oxidize hemoglobin to methemoglobin.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Lidocaine and prilocaine are metabolized in the liver; lidocaine metabolites (primarily 4-hydroxyxylidine) and prilocaine metabolites (primarily o-toluidine) are excreted renally. Less than 5% of unchanged lidocaine and prilocaine are excreted unchanged in urine. Fecal excretion is negligible.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Lidocaine: 65-70% bound to alpha-1-acid glycoprotein and albumin. Prilocaine: 55% bound to albumin.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Lidocaine: Vd approximately 1.0-1.5 L/kg; prilocaine: Vd approximately 1.5-2.0 L/kg. Clinical meaning: Large Vd indicates extensive tissue distribution, including into the CNS and adipose tissue.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Topical bioavailability: 20-30% for lidocaine and prilocaine when applied to intact skin under occlusion; higher (up to 80%) on mucous membranes or abraded skin. Systemic absorption is minimal with recommended doses, but can be significant with prolonged application or large surface areas.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
No dose adjustment required for renal impairment; however, use with caution in patients with severe renal impairment due to potential accumulation of lidocaine and prilocaine metabolites.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
In Child-Pugh Class B or C, use with caution and consider reduced application area or shorter application time due to reduced metabolism of lidocaine and prilocaine; specific dose modifications not established.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Infants and children: Apply 1-2 g per 10 cm², with maximum application area based on weight: 10 cm² for infants 1-3 months, 20 cm² for 3-12 months, 100 cm² for 1-6 years, 200 cm² for 7-12 years; application time 30-60 minutes depending on age and procedure.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
No specific dose adjustment; use with caution in elderly due to increased risk of systemic absorption from thinner skin and potential comorbidities; consider smaller application area or shorter duration.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
EMLA cream can cause methemoglobinemia, especially in children under 12 months, patients with glucose-6-phosphate dehydrogenase deficiency, or those taking oxidizing drugs. Serious and fatal methemoglobinemia has been reported; monitor for signs and symptoms.
There is no FDA black box warning for ALPHACAINE.
Avoid application to open wounds, mucous membranes (except genital), or areas with altered skin barrier. Use with caution in patients with severely traumatized mucosa or sepsis. Monitor for methemoglobinemia, especially in young children. Do not apply to large areas or for prolonged periods. Consider risk of systemic toxicity if applied to inflamed skin or large areas.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Hypersensitivity to lidocaine, prilocaine, or other amide anesthetics; known history of methemoglobinemia; application to eyes or on tympanic membrane; patients with severe hepatic disease (due to impaired metabolism).
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
No known food interactions. Avoid alcohol if large amounts of lidocaine/prilocaine are absorbed (rare).
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
EMLA (lidocaine 2.5% and prilocaine 2.5%) is FDA Pregnancy Category B. Lidocaine and prilocaine cross the placenta. In first trimester, no increased risk of major malformations in human data. Second and third trimesters: no known fetal harm from topical use. Methemoglobinemia risk in fetus if high doses or prolonged use, especially with prilocaine.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Lidocaine and prilocaine are excreted into breast milk in low amounts. M/P ratio: lidocaine ~0.4-0.6, prilocaine ~1.0-1.4. Infant dose ~1-2% of maternal weight-adjusted dose. Risk of methemoglobinemia in premature or G6PD-deficient infants. Use with caution.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
No specific dose adjustments required for topical application. Physiologic changes in pregnancy (increased plasma volume, decreased protein binding) do not significantly alter systemic absorption from intact skin. Avoid large areas, prolonged application, or abraded skin to minimize systemic load.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
EMLA (eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) requires at least 60 minutes of occlusive application for dermal analgesia. Apply to intact skin only; avoid mucous membranes due to rapid absorption. Do not use in infants <37 weeks postconceptual age due to methemoglobinemia risk. Maximum application area: 10% body surface in infants. Onset is slower on thicker skin (e.g., back vs. antecubital). Remove cream after 4 hours to prevent systemic toxicity.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Apply a thick layer (1-2 mm) to intact skin and cover with occlusive dressing for at least 60 minutes before procedure.,Do not use on broken skin, eyes, or near mucous membranes.,Wash hands after application and avoid touching eyes.,Remove cream and dressing just before procedure; do not leave on longer than 4 hours.,Possible mild skin reactions: blanching, redness, swelling. Serious allergic reactions are rare but seek medical help if difficulty breathing or hives occur.,Inform your doctor if you have liver disease, G6PD deficiency, or are taking other numbing medicines.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMLA vs ALPHACAINE, answered by our medical review team.
EMLA is a Local Anesthetic that works by EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMLA and ALPHACAINE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMLA is: Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMLA and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMLA is classified as Category C. EMLA (lidocaine 2.5% and prilocaine 2.5%) is FDA Pregnancy Category B. Lidocaine and prilocaine cross the placenta. In first trimester, no increased risk of major malformations in . ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.